[1]
|
Shadhu, K. and Xi, C. (2019) Inflammation and Pancreatic Cancer: An Updated Review. Saudi Journal of Gastroenter-ology, 25, 3-13. https://doi.org/10.4103/sjg.SJG_390_18
|
[2]
|
Rahib, L., Smith, B.D., Aizenberg, R., et al. (2014) Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research, 74, 2913-2921.
https://doi.org/10.1158/0008-5472.CAN-14-0155
|
[3]
|
Padoan, A., Plebani, M. and Basso, D. (2019) Inflammation and Pancreatic Cancer: Focus on Metabolism, Cytokines, and Immunity. International Journal of Molecular Sciences, 20, Article No. 676. https://doi.org/10.3390/ijms20030676
|
[4]
|
McGuigan, A., Kelly, P., Turkington, R.C., et al. (2018) Pancreatic Cancer: A Review of Clinical Diagnosis, Epidemiology, Treatment and Outcomes. World Journal of Gastroenterology, 24, 4846-4861.
https://doi.org/10.3748/wjg.v24.i43.4846
|
[5]
|
Loveday, B.P.T., Lipton, L. and Thomson, B.N. (2019) Pancreatic Cancer: An Update on Diagnosis and Management. Australian Journal of General Practice, 48, 826-831. https://doi.org/10.31128/AJGP-06-19-4957
|
[6]
|
Stone, M.L. and Beatty, G.L. (2019) Cellular Determinants and Therapeutic Implications of Inflammation in Pancreatic Cancer. Pharmacology & Therapeutics, 201, 202-213. https://doi.org/10.1016/j.pharmthera.2019.05.012
|
[7]
|
Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Can-cer: The Next Generation. Cell, 144, 646-674.
https://doi.org/10.1016/j.cell.2011.02.013
|
[8]
|
Allen, J., Cernik, C., Bajwa, S., et al. (2020) Association of Neu-trophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer. Journal of Clinical Medicine, 9, Article No. 3283.
https://doi.org/10.3390/jcm9103283
|
[9]
|
Hu, R.J., Ma, J.Y. and Hu, G. (2018) Lymphocyte-to-Monocyte Ratio in Pancreatic Cancer: Prognostic Significance and Meta-Analysis. Clinica Chimica Acta, 481, 142-146. https://doi.org/10.1016/j.cca.2018.03.008
|
[10]
|
Asaoka, T., Miyamoto, A., Maeda, S., et al. (2016) Prognostic Im-pact of Preoperative NLR and CA19-9 in Pancreatic Cancer. Pancreatology, 16, 434-440. https://doi.org/10.1016/j.pan.2015.10.006
|
[11]
|
Iwai, N., Okuda, T., Sakagami, J., et al. (2020) Neutrophil to Lym-phocyte Ratio Predicts Prognosis in Unresectable Pancreatic Cancer. Scientific Reports, 10, Article No. 18758. https://doi.org/10.1038/s41598-020-75745-8
|
[12]
|
Xiang, Z.J., Hu, T., Wang, Y., Wang, H., Xu, L., et al. (2020) Neutrophil-Lymphocyte Ratio (NLR) Was Associated with Prognosis and Immunomodulatory in Patients with Pancreatic Ductal Adenocarcinoma (PDAC). BioScientific Reports, 40, BSR20201190. https://doi.org/10.1042/BSR20201190
|
[13]
|
Pavan, A., Calvetti, L., Dal Maso, A., et al. (2019) Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Im-mune-Checkpoint Inhibitors. Oncologist, 24, 1128-1136.
https://doi.org/10.1634/theoncologist.2018-0563
|
[14]
|
Fogar, P., Sperti, C., Basso, D., et al. (2006) Decreased To-tal Lymphocyte Counts in Pancreatic Cancer: An Index of Adverse Outcome. Pancreas, 32, 22-28. https://doi.org/10.1097/01.mpa.0000188305.90290.50
|
[15]
|
Bellone, G., Turletti, A., Artusio, E., Mareschi, K., et al. (1999) Tumor-Associated Transforming Growth Factor-Beta and Interleukin-10 Contribute to a Systemic Th2 Immune Phenotype in Pancreatic Carcinoma Patients. The American Journal of Pathology, 155, 537-547. https://doi.org/10.1016/S0002-9440(10)65149-8
|
[16]
|
Tang, X., Zhang, M., Sun, L., Xu, F., et al. (2021) The Bio-logical Function Delineated across Pan-Cancer Levels through lncRNA-Based Prognostic Risk Assessment Factors for Pancreatic Cancer. Frontiers in Cell and Developmental Biology, 9, Article ID: 694652. https://doi.org/10.3389/fcell.2021.694652
|
[17]
|
Ben, Q., An, W., Wang, L., et al. (2015) Validation of the Pretreat-ment Neutrophil-Lymphocyte Ratio as a Predictor of Overall Survival in a Cohort of Patients with Pancreatic Ductal Ad-enocarcinoma. Pancreas, 44, 471-477.
https://doi.org/10.1097/MPA.0000000000000271
|
[18]
|
Ponath, V., Frech, M., Bittermann, M., et al. (2020) The Oncoprotein SKI Acts as a Suppressor of NK Cell-Mediated Immunosurveillance in PDAC. Cancers (Basel), 12, Article No. 2857. https://doi.org/10.3390/cancers12102857
|
[19]
|
Arima, K., Okabe, H., Hashimoto, D., et al. (2016) The Diagnostic Role of the Neutrophil-to-Lymphocyte Ratio in Predicting Pancreatic Ductal Adenocarcinoma in Patients with Pancreatic Diseases. International Journal of Clinical Oncology, 21, 940-945. https://doi.org/10.1007/s10147-016-0975-z
|
[20]
|
Suzuki, R., Takagi, T., Hikichi, T., et al. (2016) Derived Neutro-phil/Lymphocyte Ratio Predicts Gemcitabine Therapy Outcome in Unresectable Pancreatic Cancer. Oncology Letters, 11, 3441-3445. https://doi.org/10.3892/ol.2016.4381
|